• The company anticipates continuation of Direct Solar’s success, projecting $5 million in contracts by the end of 2019
• Direct Solar has added a new arm, Direct Solar Capital, in an effort to reach untapped markets
• SinglePoint’s CEO projects that the company will reach $15 million in sales by next year

SinglePoint Inc. (OTCQB: SING) CEO Greg Lambrecht joined Donald Baillargeon on MoneyTV (http://ibn.fm/j57j0) to continue an interview regarding the company’s recent acquisition of Direct Solar. During its first 30 days with SING, Direct Solar brought in $1.7 million in contracts; that same showing was repeated during the next 30 days. SING and Direct Solar anticipate a continuation of this performance, which equates to a path to $5 million by year end.

This acquisition has broadened and changed the company. “It has changed how we are thinking of some of the other projects that we are trying to incubate,” Lambrecht noted in the interview. “Some of them we’ve just sat down with the chalkboard and said, quite frankly, let’s focus more on solar – and CBD, for that matter. Because both of the projects and businesses are going extremely well.”

Currently, Direct Sales’ numbers represent only residential contracts; however, that is about to change. To serve medium commercial outfits, Direct Solar has added a new arm, Direct Solar Capital, as an alternative-energy financing solution (http://ibn.fm/1kgcl). Businesses that have an alternative energy project ready to go will now have access to anywhere from $50,000 to $3 million in funding.

From day one, Direct Solar Capital was built on a solid foundation, making it ready to begin processing applications immediately. “Even though it has only been a couple days since our last announcement, we have already started to receive a great deal of interest in our ability to finance projects,” Allen Kruse, marketing director for Direct Solar of America, stated in a news release (http://ibn.fm/6ABRf).

Commercial contracts that provide economic benefit to both customer and contractors are providing a new revenue stream for Direct Solar. This is a relatively untapped market. Prior to this agreement, midsize businesses had limited viable access to solar energy due to limited funding options. The solar brokerage model is proving to be a highly valued commodity within the market.

Commercial solar applications and renewable-energy financing solutions are inspiring SING to look creatively toward the future as the company seeks out additional innovative marketing strategies without sacrificing the its core offerings. SING and Direct Solar are working on an application that streamlines the purchase of solar even further by providing online access to quotes, solar shopping and scheduling of onsite visits.

The success of Direct Solar is creating a solid financial base for SING as it continues to expand and seek out additional acquisitions. “The traction we have experienced so far has been amazing,” Direct Solar Founder Pablo Diaz stated in a news release (http://ibn.fm/gtfV2). “We are thrilled for the achievements we have accomplished and are looking forward to continually improving. We are now exploring ways to generate additional sales through innovative marketing strategies. I’m confident we will hit $15 million in 2020.”

Singlepoint acquires small to mid-sized businesses. The company’s focus is on new technologies. Investments in renewable energy, legal ancillary cannabis and hemp are only a few examples of the multiple industries and verticals included in SinglePoint’s diversified portfolio. By investing in undervalued subsidiaries, the company has grown from a full-service mobile technology provider to a recognizable brand with multiple revenue streams. The company is currently seeing exponential growth due to its involvement in alternative energy.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Marijuana Company of America is based in the United States and has begun launching its cannabidiol (CBD) products in the United Kingdom and Europe
• The cannabis and hemp industries are expected to be worth $66.3 billion worldwide by 2025
• The CBD market in Europe is expected to grow by more than 400 percent through 2023
• MCOA’s revenues increased by 840 percent year-over-year during 2018 and, at the end of the first quarter of this year, were up by 504 percent year-over-year

Marijuana Company of America Inc. (OTCQB: MCOA) has been flexing its muscle in the cannabis and hemp industries during recent months by building inroads to California’s world-leading market while also expanding into the international arena. The company is developing a diversified income base that provides a measure of security to shareholders while increasing its presence in a fledgling space that has exploded to such a degree that the industry is expected to hold a $66.3 billion global capitalization by 2025, growing at a CAGR of 23.9 percent, according to Grand View Research Inc. analysis (http://ibn.fm/yUslJ).

MCOA noted in June that it had successfully launched its hempSMART subsidiary’s products in Scotland, selling out its cache and signing up of numerous new marketing associates (http://ibn.fm/bEong). The company followed up on the news by reporting that it had advanced into the Netherlands with its prime quality botanical ingredients, again selling out the cache of products that representatives had taken with them.

“The Netherlands launch was a complete success, with people traveling from other parts of Europe to witness the excitement around our hempSMART CBD product line,” Global Sales Director Ian Harvey stated in a news release (http://ibn.fm/kQfXG). “Our high-quality CBD products combined with our compilation of highly knowledgeable hempSMART team members have effectively increased the company’s footprint into the compelling European market.”

Analysts at predictive market intelligence company The Brightfield Group issued a forecast calling for the cannabidiol market in Europe to grow by more than 400 percent from 2018 to 2023, increasing from a starting value of about $318 million, according to MCOA’s report on the Netherlands launch.

As young as the cannabis sector is in North America, it’s even newer in Europe, and, as the tide of interest begins to turn there, Canadian companies are leveraging their power to raise money legally and aggressively go after new opportunities in the making across the Atlantic (http://ibn.fm/9scyQ).

MCOA’s investments and joint ventures (http://ibn.fm/g7mPQ) form a portfolio of businesses based in the United States that are intent on improving the quality of life of customers through “healthy, sustainable alternatives to many products currently on the market.” Because it is headquartered in the state-legal cannabis arena of California – the world’s largest marketplace – the company is also finding itself in prime position to build a competitive presence overseas.

“As Marijuana Company of America embarks on 2019, we find ourselves with many new partners, joint venture relationships and a very powerful consortium of companies who share our strategic global vision,” CEO Don Steinberg stated in a letter to shareholders in May (http://ibn.fm/DgZUO). “Building a global network marketing company with organizations in dozens of countries is challenging, fun, educational and rewarding. We look forward to the future of this company as we roll out our global business plan.”

The company’s year-end financials report issued in April noted an 840 percent year-over-year increase in revenue and a gross profit margin of 68 percent, followed by a reported 504 percent year-over-year revenue increase for the first quarter of 2019 with gross margins of 65.3 percent (http://ibn.fm/gfWCs).

“Our passion from the beginning has been on our hempSMART wellness products, which continue to successfully generate demand and interest worldwide. As a result, we have significantly expanded our hemp research and growth business,” Steinberg added. “With our powerful consortium of partners and joint venture relationships, we believe we are strategically positioned to vertically integrate our operations and further increase our revenue potential.”

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Spectrum Global Solutions is professionally registered in 49 states, three U.S. territories and six Canadian provinces
• Carriers, consumers and enterprises are projected to spend $1.5 trillion on telecommunications services
• The ongoing 5G rollout is forecast to create three million American jobs and drive over $500 billion in U.S. GDP growth
• SGSI, trusted and qualified to build and service end-to-end communication networks, has a proven track record with top-tier Fortune 1,000 companies worldwide

Leading telecommunications engineering and infrastructure services provider Spectrum Global Solutions Inc. (OTCQB: SGSI) is trusted worldwide to engineer, upgrade, install and maintain next-generation telecommunications networks. SGSI’s customers include some of the largest and most respected firms in the high-growth telecom industry, which is forecast to grow to nearly $1.5 trillion in value by 2020, according to Statista (http://ibn.fm/u2J2t).

Worldwide, the number of mobile connections is predicted to reach nine billion by 2020 – roughly twice the amount in 2009 – with spending on wireless data telecommunications forecast to reach nearly $500 billion by the end of 2019, per Statista. Recognized as one of the few elite, nationwide, full-service engineering, construction, installation, maintenance and professional service firms, SGSI has successfully executed projects across the U.S. and around the globe (http://ibn.fm/R4HPI).

SGSI President Keith Hayter noted in an interview with RedChip Money Report that the market opportunity is immense and one that Spectrum Global Solutions is well positioned to serve (http://ibn.fm/ZdJyC).

“Over $1.5 trillion is going to be spent on telecommunications,” Hayter stated in the interview. “For deployment services, which is where we primarily fit in and get our revenue streams from, from $150 (billion) to $200 billion will be spent over the next couple of years.”

As a holding company for next-generation technology firms specializing in the telecommunications industry across North America and Europe, SGSI recently reported its first quarter financial results, with positive income from operations and a year-over-year increase in revenues from $4.3 million to $11.3 million (http://ibn.fm/bEsBb). SGSI subsidiaries AW Solutions, ADEX and TNS provided consistent revenue growth – a pattern that is expected to continue, CEO Roger Ponder stated in the release.

SGSI sees market growth in future 5G implementation from telecom firms, as well as ongoing 4G network upgrades. The company has positioned itself to gain more market share and will seek to maximize cross-selling opportunities by leveraging services and relationships with clients of operating subsidiaries.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• In a chairman announcement, HTC Extraction Systems shed some light on the ongoing expansion of its buildout and biomass drying infrastructure
• The company also discussed the unexpectedly fast growth of its hemp crops in Saskatchewan
• Additional testing suggests that the main plant variety forming the largest portion of the harvest will contain higher-than-anticipated CBD levels

HTC PureEnergy Inc. (TSX.V: HTC) (dba HTC Extraction Systems), an advanced extraction and purification technology company, announced on July 31, 2019, that its hemp crops in Saskatchewan have grown at an advanced rate that exceeds expectations. Additionally, testing of the plant variety that makes up over 60 percent of the harvest shows higher than anticipated CBD levels.

The company is actively working to expand the capacity of its buildout and biomass drying infrastructure. As per a recent HTC Extraction Systems chairman message, the dryer’s bag house has been installed, the control office trailer and the conveyor belt have been delivered and the propane tank pad has been placed.

Currently, HTC Extraction Systems is in the exterior lockup phase of the extraction building. The drying and processing system is scheduled to go live on April 15.

HTC Extraction Systems and the company’s subsidiaries have developed proprietary gas, liquid and biomass extraction and purification systems that have been designed to extract from gas, liquids and biomass for the distillation and purification of ethanol and ethanol-based solvents used for the generation of clean energy and within the hemp/biomass industries.

One of the primary focal points in the HTC Extraction Systems operations is environmental sustainability. Through its proprietary technologies, the company is rapidly moving toward reducing its environmental footprint and relying on reduce, reuse, recycle methodologies.

A few examples of the advanced HTC Extraction Systems technologies include LCDesign(TM) (low cost design for modular gas, liquid and biomass extraction systems), PDO Engine(TM) (software-based design algorithms that can accurately model biomass extraction processing) and Data Solvents(TM) (custom-designed ethanol-based solvent mixtures and additives that optimize production and reduce costs).

Currently, HTC Extraction Systems is working on its seeded hemp and biomass drying infrastructure, as well as the GMP Euro-certified extraction, purification and refining center.

In June 2019, HTC Extraction Systems announced a hemp biomass tolling agreement involving the supply of hemp biomass for the 2019 crop year from its hemp grown in Saskatchewan. The company utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. Initial estimates suggest that the company will be processing five million kilograms of hemp biomass and extracting CBD FSO distillate.

As a tolling fee payment, HTC Extraction Systems will be receiving a percentage of the extracted CBD FSO distillate.

HTC Extraction Systems is negotiating its entry into a tolling contract with a 60,000-acre Canadian farm leader and recognized producer. Upon its finalization, the agreement is expected to remain valid until 2021.

For more information, visit the company’s website at www.HTCExtraction.com

• Medical marijuana products could soon be available in licensed Louisiana dispensaries, presenting opportunity for VPR Brands
• The company’s FY2018 financials show impressive growth
• VPR Brands recently launched the HRB Turbo Dry Herb Vaporizer by HoneyStick

VPR Brands LP (OTC: VPRB) is a technology holding company based in Fort Lauderdale, Florida, whose assets include patented, atomization-related products and technology. Marijuana industry watchers believe that the long wait for VPR Brands is showing signs of coming to an end, as legislation bodes well for those waiting to benefit from medical marijuana.

Early this week, officials from the Louisiana Department of Agriculture and Forestry (LDAF) announced that medical marijuana products could be available in licensed dispensaries as soon as next week. This news has been a long time coming for both patients and dispensary owners, who have endured countless delays since 2015, when voters approved a measure to legalize medical cannabis (http://ibn.fm/jLkv7).

In more good news for the company, VPR Brands announced its 2018 financial results, posting increased revenues and a narrowed net loss as compared to 2017. Full-year gross operating margins for 2018 increased by almost 20 percent from 2017, to a margin of 41 percent in 2018 (http://ibn.fm/z3RBB).

Finally, VPR Brands recently launched its HRB Turbo Dry Herb Vaporizer by HoneyStick. The HRB Turbo is an ultra-premium, pocket-sized dry-herb vaporizer available for only $99. “The HRB Turbo is the best dry-herb vaporizer with an MSRP under $100 currently on the market,” VPR Brands COO Dan Hoff stated in a news release (http://ibn.fm/jrhPJ).

VPR Brands LP continues to drive scale across diverse high-growth verticals. The company’s current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate its products within the vaping industry.

VPR Brands has a seasoned management team with wide-ranging experience in the vaporizer category. CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. The company employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Earth Science Tech operates through diverse subsidiaries in the CBD space
• The company offers a wide range of CBD products, as well as its MSN-2 medical device
• ETST has varied distribution agreements in place to strengthen its foothold in the CBD marketplace

Earth Science Tech Inc. (OTCQB: ETST) is a biotechnology company operating in varied and vibrant market sectors, including hemp cannabidiol (CBD), nutraceuticals, pharmaceuticals and medical-device research and development. Headquartered in Doral, Florida, the company functions by way of diverse, wholly owned subsidiaries centered on developing its role as a global leader in the CBD space. These subsidiaries are also expanding Earth Science Tech’s work in the pharmaceutical and medical-device sectors.

Earth Science Pharmaceutical Inc. is one of the company’s subsidiaries. Its emphasis is on becoming a worldwide leader in the development of low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases) (http://ibn.fm/lrECC). The first medical device offered by Earth Science Pharmaceutical is the MSN-2 Chlamydia Home Kit Screening, designed to detect STIs.

The company’s technology depends on the use of a modified panty liner (MSN-2) worn for four hours to collect a sample of human cells. The liner is then sent to a designated lab, where the cells are subsequently analyzed employing a proven and established process. Modified panty liners have less- strict transport criteria than urine or vaginal swabs. The company is advancing clinical trials of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://ibn.fm/wnCtn).

Another subsidiary of Earth Science Tech is Cannabis Therapeutics Inc. Cannabis Therapeutics is committed to become a global leader in cannabinoid research and development (R&D) for an extensive line of cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions. Its mission is to help change the health care landscape by introducing proprietary products made for the global pharmaceutical- and retail-consumer markets.

Cannabis Therapeutics has a provisional application patent for CBD and is invested in R&D to explore and harness the medicinal power of cannabidiol. The company is working to develop CBD-based drugs and nutraceutical products and is also working to integrate CBD molecules with existing generic drug molecules. Cannabis Therapeutics is concentrating on developing pioneering products that provide treatment options for patients and physicians.

Furthermore, Earth Science Tech has its Canna Inno Laboratories Inc. subsidiary. Earth Science Tech established this subsidiary in 2017 to carve out a position in the Canadian province of Québec, giving ETST inside access to the thriving Canadian CBD market. Canna Inno Laboratories provides ETST with access to government grants offered to innovators in the pharmaceutical industry; Canna Inno’s first grant has received approval (http://ibn.fm/veTzP).

Overall, Earth Science Tech offers its unique product lineup in varied forms including liquids, tablets, capsules, soft gels, sprays, chewables, creams, whole herbs and powders. The company’s product family includes CBD oil for pets, flavored and infused CBD oils and a line of organic chocolate CBD products. The company’s CBD oil is 100 percent natural and organic and is manufactured using a supercritical CO2 liquid extraction process.

Earth Science Tech also has key distribution agreements in place to further the market reach of its products. This year, the company signed agreements to distribute CBD products via pharmacies, chiropractors, dispensaries, athletic clubs and clinics (http://ibn.fm/6OWnD). ETST is advancing product placement in large chains, health-food stores and other establishments, and the agreements are for the distribution of a high-grade, full-spectrum cannabinoid line. Agreements are in place with CannaBiz and Desert Sun Distribution.

Moreover, Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to work on projects that scientifically support and advance the health care benefits of the company’s high-grade, hemp-CBD oil.

Earth Science Tech continues to focus on the new frontier involving the innovative integration of CBD with generic drug molecules. With a management team that has decades of invaluable experience in the nutraceutical, dietary supplement, and life sciences sectors, ETST offers investors an attractive opportunity in the emerging CBD space. Earth Science Tech remains dedicated to growing its product portfolio and customer base.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Supreme Cannabis recently debuted its platform to pursue opportunities in the UK and European CBD health and wellness markets
• The launch comes as Supreme Cannabis continues to advance toward an acquisition of Truverra Inc. and its subsidiary, which sells CBD products in select European markets
• The strategic move provides investors with exposure to the fast-growing European CBD space

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is intensifying its focus on Europe with the launch of London-based investment platform Supreme Heights. In addition, the company’s previously announced acquisition of privately held, Toronto-based Truverra Inc. is expected to close by August 30.

Supreme Heights will better enable Supreme Cannabis to make strategic moves in the CBD health and wellness space in the United Kingdom and Europe. Supreme Cannabis is structured to provide support services for premium brands, as well as CBD offerings (http://ibn.fm/ky5LV).

“Supreme Cannabis is positioned to quickly act on attractive opportunities and establish an early mover advantage in the space,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “Supreme Heights will benefit from our experience launching some of the most premium cannabis brands in Canada and from the strong leadership and the deep industry connections of our UK partners.”

Supreme Heights CEO Patrick Morton said that, with the guidance of Supreme Cannabis, his company would seek to make targeted investments in value-add categories and diverse segments including vaporizers, edibles, beverages, topicals and ancillary services.

In addition to gaining advanced infrastructure and manufacturing capabilities, the acquisition of Truverra offers Supreme Cannabis opportunities to address the international medical market. The companies announced that Truverra would serve as Supreme Cannabis’s global medical brand, building on an existing R&D platform as well as established CBD offerings within Europe.

A Truverra subsidiary, which Supreme Cannabis will also acquire, Netherlands-based Truverra Europe sells hemp-based CBD products in select markets in Europe (http://ibn.fm/ty6Ph). The transaction for 14.7 million common shares of Supreme Cannabis has a value of approximately C$20 million (http://ibn.fm/xwiqW). Truverra Europe will give Supreme Cannabis another distribution point in Europe. These acquisitions support the company’s larger goal of creating new cannabis opportunities across the globe.

Supreme Cannabis is a Toronto-based company focusing on pursuing opportunities and generating sustainable growth in what it sees as an emerging global market. The company’s portfolio includes 7ACRES, an award-winning brand; Blissco, a wellness cannabis brand and licensed producer; Cambium Plant Sciences, a cultivation IP and plant genetics company; Medigrow Lesotho, a Southern Africa cannabis oil producer; Supreme Heights, an investment platform focused on CBD; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Lionsgate’s Globalgate consortium plays a significant role in the media powerhouse’s efforts at world connectivity through a film-financing structure that harnesses “the upside of international film production”
• Globalgate’s partnership with France’s TF1 Studios marks its 13th partnership aimed at taking advantage of the worldwide boom in local-language features by remaking local hits for non-U.S. markets
• Lionsgate recently launched its first movie-themed amusement park on an island conveniently situated near Macau’s gaming empires and Hong Kong’s international business communities
• The company plans to open a movie-themed park on South Korea’s Jeju Island next year
• China’s amusement park industry is projected to bring in $12 billion in annual revenues by next year

World entertainment content powerhouse Lions Gate Entertainment Corp. (NYSE: LGF.A) (NYSE: LGF.B) continues to build a global, vertically oriented profile offering ways for people to connect with each other and have fun through a variety of innovative platforms. One way that the company is demonstrating its potential for bridging global divides through its revenue-generating activities was manifest in a recent partnership with TF1 Studios, the theatrical division of French commercial television company TF1 Group (http://ibn.fm/zPrk1).

TF1 Studios will provide local French theatrical content for remakes that are primarily marketed to other non-U.S. markets outside France. TF1’s partnership with Lionsgate’s Globalgate content platform grants the local-language film company its 13th curated working production and distribution partner under an umbrella that includes studios such as Mexico’s Televisa, Tobis in Germany, RAI Cinema in Italy and Kadokawa in Japan.

Globalgate uses “a distributor-aligned film-financing structure to harness the upside of international film production” in a variety of foreign markets (http://ibn.fm/GN5ve). The company currently has more than 40 films and series in development, including remakes of Mexican hit Instructions Not Included for the Indian and Korean markets; Argentine romance comedy No Kids for Germany, Korea and Mexico; and Korean action-thriller Terror Live for the Japanese and Indian markets.

“Globalgate has successfully harnessed the fast-growing local content market and their growing roster of blue-chip production and distribution partners is both very compatible with TF1 Studio and will advance our footing in France and globally,” TF1 Studio Deputy CEO Nathalie Toulza Madar stated in a news release.

Lionsgate’s most recent global project is its Lionsgate Entertainment World high-tech, movie-themed amusement park on China’s Hengqin Island, situated near Hong Kong and Macau. The 240,000-square-foot vertically constructed indoor park opened July 31, offering visitors an immersive experience, with 25 attractions built around Lionsgate’s film properties The Hunger Games, Twilight, Divergent, Escape Plan, Now You See Me and Gods Of Egypt (http://ibn.fm/pxaEL).

The amusement park is a key component of the Novotown development, which is focused on non-gaming tourism just across the water from Macau’s “Las Vegas of Asia” casino and shopping attractions, as well as Hong Kong’s nearby international business population. The development itself is part of the Chinese central government’s plan to link the economies of Macau, Hong Kong and major cities in Guangdong Province, where Hengqin Island is located, following suggestions by Macau’s gaming industry that relaxed border formalities between Hengqin and Macau should be encouraged in order to boost tourism trade between the two (http://ibn.fm/peWTP).

Market analysts at World Travel Market anticipate that China’s booming theme park industry could draw revenues of $12 billion by 2020 (http://ibn.fm/fkKez), which would mark an increase of 367 percent from 2010 as the country’s middle income demographic expands.

Movie-themed attractions have long been the focus of tourism agencies in sun-drenched cities, and Lionsgate’s move to join in the market potential grants the company a significant Asian young adult customer base. The company had earlier planned to launch a similar amusement park in New York’s Times Square as the first entry in its strategy of building branded indoor entertainment centers in high-traffic urban areas in major U.S. and European cities, but, in July, Lionsgate announced that it was abandoning the New York site (http://ibn.fm/XIGqd).

The company plans to open its Lionsgate Movie World outdoor theme park on Jeju Island in South Korea next year, and it continues to operate other, smaller theatrical-themed entertainment centers around the world, including live stage attractions such as the Lionsgate Zone of the Motiongate theme park in Dubai, the Saw Escape Room in Las Vegas and the touring Hunger Gamez exhibition.

For more information, visit the company’s website at www.Lionsgate.com

• First Bitcoin Capital is advancing its status as a blockchain tech developer by acquiring the nation’s first bitcoin ATM patent, which it believes controls all bitcoin ATMs and kiosks in the United States
• First Bitcoin is preparing to enforce its patent rights, which it predicts should be worth more than $50 million in profits during the coming five years
• More than 3,000 bitcoin ATMs are currently operating in the United States, and an average of 3.7 bitcoin ATMs are being added each day
• First Bitcoin is also launching an ATM check-cashing service for unbanked payday customers, and it expects to add money order services and bitcoin buying/selling options through a nationwide network of SAMCO kiosks

First Bitcoin Capital Corp. (OTC: BITCF), a blockchain-powered technology developer that has created more than 100 unique cryptocurrencies during its history, is preparing to make a revolutionary leap in its revenue generation following its acquisition of the ‘bitcoin ATM patent’ (http://ibn.fm/COpsb), which it intends to use in governing the more than 3,000 bitcoin ATMs – and growing – operated in the United States.

Bitcoin ATMs are novel machines built on the model of a standard banking ATM, but they allow their users to instantly buy or sell bitcoin and other cryptocurrencies using cash or tokens, without any expectation of a bank account’s involvement in the transaction – although debit and credit cards are accepted.

The patent covers the mechanism that manages the purchase and sale of cryptocurrencies at the kiosks. Industry watcher Coin ATM Radar states that a daily average of 3.7 bitcoin ATM installations were occurring in the United States as of July (http://ibn.fm/ZUJco), and First Bitcoin stated in its news release announcing the acquisition that a business plan prepared by a third party predicts that the patent will bring in more than $50 million in profits over the coming five years.

The company is establishing its strategies for implementing an IP management plan, and it predicts that the patent could have a significant impact on the cryptocurrency industry itself.

“All bitcoin ATMs and kiosks manufactured and sold in the U.S., and all bitcoin ATMs and kiosks operated in the U.S. are believed to be subject to this patent and the company intends to enforce its right upon acquisition of same. The company has already begun negotiations with a major law firm that has a very successful track record in enforcing patent rights when working on a contingency basis,” the news release states (http://ibn.fm/FRYce).

Patenting bitcoin ATMs has been the subject of corporate competition in recent months. DNA Dynamics announced (http://ibn.fm/H3H2D) that it hoped to control “a crucial patent that requires any bitcoin ATM operator to give a royalty on every bitcoin ATM transaction throughout the U.S.,” for example, and Bank of America filed its own statement of interest (http://ibn.fm/4rehC) in technology that uses blockchain to “accelerate transaction speed and/or facilitate other types of transactions in addition to ATM transactions like cash withdrawals and deposits, such as gift registry transactions.”

“Being the first ever publicly traded company in the bitcoin and blockchain industry, we now have acquired one of the most important intellectual properties in this space, as we believe that this patent will provide us a unique and leveraged position, in addition to our other projects as we continue moving forward into the digital asset and cryptocurrency businesses,” First Bitcoin CEO Greg Rubin stated in a news release. “This patent complements our innovation in the field.”

First Bitcoin is developing its ATM presence by launching a pilot test program through which it has ordered Simple Automated Money, Inc. (SAMCO)’s S.A.M. kiosks to integrate bitcoin ATM into self-service check cashing kiosks nationwide, beginning with three kiosks in Northern California. The ATMs will grant unbanked consumers a fast and confidential check-cashing experience through SAMCO’s web-enabled units (http://ibn.fm/HBZSU).

First Bitcoin stated that it is expanding its California dispensary ATM locations to include C-stores and supermarkets. The company announced that it will also begin to add bitcoin buy/sell capabilities through the nationwide network of 85 SAMCO kiosks currently in operation, as well as money order processing and check cashing through touchscreen, biometric-secured access.

For more information, visit the company’s website at www.FirstBitcoin.io

• INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
• Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
• The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://ibn.fm/4pBdZ).

“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in a news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”

A fast-growing cancer patient population that is resistant to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy’. During his presentation, Tesi reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients (http://ibn.fm/m1Iy3).

“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”

The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.

Tesi is also speaking on ‘Next-Generation Immunotherapies’ and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides a unique opportunity to network with decision-makers, build lasting collaborations and gain actionable solutions.

INmune Bio also recently attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan, where Tesi gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’. His presentation centered on monotherapy with checkpoint inhibitors (“CPI”) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, an article explains (http://ibn.fm/EFAdX).

INmune Bio’s product pipeline targets three segments of concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the U.S.; cancer residual disease, which is expected to generate more than 1.7 million new cases yearly; and resistance to immunotherapy. INmune Bio is currently working on three product platforms: INKmune and INB03, which modify a patient’s innate immune response to cancer; and XPro1595, which targets inflammation linked to Alzheimer’s disease.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB